| Jun 4 |
Viking Therapeutics gains on additional data for NASH drug
|
| Jun 4 |
Viking says biopsy data confirm MASH drug’s benefit
|
| Jun 4 |
Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
|
| Jun 4 |
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
|
| Jun 4 |
GameStop, Exxon, Gitlab fall premarket; Intel, Viking rise
|
| Jun 3 |
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
|
| Jun 3 |
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
|
| Jun 2 |
SA Asks: Which weight-loss stocks should investors be watching?
|
| May 31 |
Here's Why Viking Therapeutics, Inc. (VKTX) Gained But Lagged the Market Today
|
| May 31 |
Here's How Much You Would Have Made Owning Viking Therapeutics Stock In The Last 5 Years
|
